Providers

Provider Resource Center

Research

Ketamine Offers Rapid Relief in Obsessive-Compulsive Disorder: A Controlled Crossover Trial

A pivotal study published in Neuropsychopharmacology presents the first randomized, controlled crossover trial demonstrating that a single dose of ketamine can have rapid anti-obsessional effects in adults with obsessive-compulsive disorder (OCD). This groundbreaking research, involving 15 drug-free participants with near-constant obsessions, shows that ketamine, a non-competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, can provide significant improvement in OCD symptoms. The trial used a double-blind, placebo-controlled design, where participants received infusions of both saline and ketamine (0.5 mg/kg). Results revealed a notable reduction in OCD symptoms during and after ketamine infusion therapy, with half of the participants meeting criteria for treatment response a week post-infusion, marking a significant advancement in OCD treatment research.

Financial Services

Manage your account or make a payment.

Disclaimers

Financing Disclaimer: We offer two financing options for the Uplift Momentum Protocol™ (medical procedure): $325/month for 12 months, with a total cost of $3,900, no down payment, 0% APR, or $1,000 down payment and $237/month for 12 months, with a total cost of $3,844, 0% APR. Approval for both plans is based on internal criteria, including bank account history and a soft credit pull. Payments may be auto-withdrawn monthly. Both plans are subject to a $25 late fee for missed payments and other terms. Cancellation within 3 days of agreement is allowed. Governed by California law and AAA arbitration rules

Individuals showcased on KetamineUplift.com are actors, the content is not reflective of their thoughts, views, or perspectives.

© 2024 Ketamine Uplift | Terms & Conditions | Privacy Policy | HIPAA Policy

Providers

Provider Resource Center

Research

Ketamine Offers Rapid Relief in Obsessive-Compulsive Disorder: A Controlled Crossover Trial

A pivotal study published in Neuropsychopharmacology presents the first randomized, controlled crossover trial demonstrating that a single dose of ketamine can have rapid anti-obsessional effects in adults with obsessive-compulsive disorder (OCD). This groundbreaking research, involving 15 drug-free participants with near-constant obsessions, shows that ketamine, a non-competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, can provide significant improvement in OCD symptoms. The trial used a double-blind, placebo-controlled design, where participants received infusions of both saline and ketamine (0.5 mg/kg). Results revealed a notable reduction in OCD symptoms during and after ketamine infusion therapy, with half of the participants meeting criteria for treatment response a week post-infusion, marking a significant advancement in OCD treatment research.

Disclaimers

Financing Disclaimer: We offer two financing options for the Uplift Momentum Protocol™ (medical procedure): $325/month for 12 months, with a total cost of $3,900, no down payment, 0% APR, or $1,000 down payment and $237/month for 12 months, with a total cost of $3,844, 0% APR. Approval for both plans is based on internal criteria, including bank account history and a soft credit pull. Payments may be auto-withdrawn monthly. Both plans are subject to a $25 late fee for missed payments and other terms. Cancellation within 3 days of agreement is allowed. Governed by California law and AAA arbitration rules

Individuals showcased on KetamineUplift.com are actors, the content is not reflective of their thoughts, views, or perspectives.

© 2024 Ketamine Uplift | Terms & Conditions | Privacy Policy | HIPAA Policy